For most women with significant perimenopausal symptoms, yes — oestrogen therapy is appropriate, evidence-based, and widely endorsed by major medical bodies worldwide, including the Menopause Society of India. The long-standing fear around hormone replacement therapy (HRT) stems largely from a misread 2002 study. Current evidence shows that for the right candidate, oestrogen therapy meaningfully improves quality of life and carries a benefit-to-risk profile that most clinicians now consider favourable.
Should I take oestrogen during perimenopause?
If your symptoms are disrupting your daily life, the answer is almost certainly yes — provided you have no specific contraindications.
Perimenopause is the transitional phase before your final menstrual period, typically lasting 4–10 years. During this time, oestrogen and progesterone levels fluctuate erratically before declining. These hormonal swings are directly responsible for the symptoms that make this phase so disruptive.
Indian women reach menopause at a median age of 46–47 years — two to three years earlier than the global average. This means perimenopause can begin in the early 40s, and symptoms can be severe well before a woman has stopped menstruating.
Oestrogen therapy works by stabilising the hormone levels your body is no longer producing reliably. It does not delay menopause. It reduces the physiological impact of the transition.
The British Menopause Society, the International Menopause Society, and the Menopause Society of India all state that HRT is appropriate for symptomatic women who do not have specific contraindications. There is no medical reason for most perimenopausal women to go untreated.
Who is a good candidate for oestrogen therapy?
Most perimenopausal women with moderate-to-severe symptoms qualify. You are a strong candidate if you experience any of the following:
- Hot flashes — sudden heat surges, flushing, sweating
- Sleep problems — night sweats, broken sleep, early waking
- Mood changes — low mood, irritability, anxiety that feels new or disproportionate
- Brain fog — difficulty concentrating, word-finding problems, memory lapses
- Joint pain — unexplained aching, especially in the morning
- Vaginal dryness — dryness, discomfort during sex, recurrent urinary infections
- Bone health concerns — early perimenopause accelerates bone density loss
You may need a more detailed conversation with your doctor before starting if you have:
- A personal history of oestrogen-sensitive breast cancer
- Unexplained vaginal bleeding (which requires investigation first)
- Active liver disease
- A personal history of blood clots (deep vein thrombosis or pulmonary embolism)
None of these are automatic disqualifiers — especially not with transdermal oestrogen — but they require individualised assessment. A menopause-aware gynaecologist is best placed to make this call with you.
What form of oestrogen is safest?
Transdermal oestrogen — delivered through a patch or gel applied to the skin — is the preferred form for most women. Here is why it matters.
Transdermal (patch or gel)
- Oestrogen is absorbed directly into the bloodstream through the skin
- Bypasses the liver entirely on first pass
- Does not increase the risk of blood clots (venous thromboembolism, or VTE)
- Produces more stable, consistent blood levels than oral tablets
- Associated with a more favourable cardiovascular risk profile
Oral oestrogen
- Passes through the liver before entering the bloodstream
- The liver responds by producing clotting proteins, raising VTE risk slightly
- Still widely used and considered safe for most women
- To put the risk in perspective: the VTE risk from oral oestrogen is still considerably lower than the risk associated with pregnancy
For women who are already at elevated clot risk — or who simply want the safest possible profile — transdermal is the clearer choice. See the hormonal treatments guide for a detailed breakdown of formulation options.
What about progesterone?
If your uterus is intact, you must take progesterone alongside oestrogen. Oestrogen alone thickens the uterine lining; progesterone protects against endometrial cancer.
- Women with an intact uterus: oestrogen + progesterone
- Women post-hysterectomy: oestrogen alone
Micronised progesterone (body-identical) is preferred over older synthetic progestogens. It carries a better tolerability profile and does not appear to add meaningfully to breast cancer risk in the short-to-medium term, unlike some older synthetic progestins.
Is oestrogen available in India?
Yes. Several formulations are available at pharmacies across India, though access varies by city and may require a prescription.
Transdermal oestrogen
| Product | Type | Approximate Cost |
|---|---|---|
| Estradot 50mcg | Patch (twice weekly) | ₹600–1,200/month |
| Climara | Patch (once weekly) | ₹600–1,200/month |
| Oestrogel | Gel (daily application) | ₹600–1,000/month |
Oral oestrogen
| Product | Type | Approximate Cost |
|---|---|---|
| Progynova | Oral tablet (estradiol valerate) | ₹300–600/month |
Progesterone
| Product | Type | Approximate Cost |
|---|---|---|
| Susten 200mg | Micronised progesterone (oral or vaginal) | ₹800–1,200/month |
Most women on a standard patch-plus-progesterone regimen spend approximately ₹1,400–2,400 per month in total. This is within reach for many urban households, though cost remains a barrier in some contexts.
The Menopause Society of India endorses HRT for appropriately selected candidates. Awareness among gynaecologists varies; seek out a menopause-aware specialist if your current doctor is hesitant without clear clinical reason.
What are the real risks of oestrogen therapy?
This question cannot be answered honestly without first correcting the record on the study that caused two decades of unnecessary fear.
The 2002 WHI study — what it actually showed
The Women’s Health Initiative (WHI) study published in 2002 caused widespread abandonment of HRT after suggesting links to breast cancer and cardiovascular disease. What was widely underreported:
- The study used conjugated equine oestrogen (from horse urine) and a synthetic progestogen — not body-identical hormones
- Participants had a mean age of 63 years — well past perimenopause
- Many had pre-existing cardiovascular disease
- The study was never designed to assess HRT in perimenopausal women
The results have been extensively reanalysed and reinterpreted since. The WHI findings do not apply to body-identical transdermal HRT started in perimenopausal women.
The critical window
Starting HRT within 10 years of menopause or before age 60 produces the best benefit-to-risk ratio. Within this window:
- Cardiovascular effects are neutral to protective — oestrogen is beneficial to arterial walls before atherosclerosis is established
- Bone protection is significant — HRT is one of the most effective interventions for preventing osteoporosis
- Brain health — emerging evidence suggests oestrogen started in the critical window may have neuroprotective effects
Starting HRT after 60, or more than 10 years after menopause, requires more careful assessment because the cardiovascular calculus changes.
Actual risks to understand
- Breast cancer: Oestrogen-alone HRT (for women without a uterus) has a different — and generally more favourable — breast cancer risk profile than combined HRT. Some studies show no increased risk; others show a small increase with long-term use. This should be discussed individually with your doctor based on your personal history. Combined HRT (oestrogen + progesterone) is associated with a small increase in risk — comparable to drinking one glass of wine daily or being overweight. These comparisons help contextualise relative risk, but absolute risk varies considerably based on age, duration of use, and individual health history — your doctor can help you understand what the numbers mean for you specifically. The risk diminishes after stopping HRT. This must be weighed against symptom severity and the benefits to bone, brain, and heart.
- Blood clots: Oral oestrogen carries a small increased VTE risk. Transdermal oestrogen does not appear to carry this risk.
- Stroke: Oral oestrogen at higher doses may slightly increase stroke risk. Transdermal oestrogen at standard doses does not appear to.
How long can I take HRT?
There is no arbitrary time limit supported by current evidence. Duration should be individualised — decided between you and a menopause-aware gynaecologist based on your symptoms, risk factors, and goals. Many women continue HRT for many years with annual review.
Making the decision
Oestrogen therapy is not a lifestyle upgrade or a vanity choice. It is a clinically appropriate treatment for a hormone deficiency that, left unaddressed, can significantly impair quality of life and long-term health.
The decision should be made with accurate information — not the fear carried over from a misread 2002 study.
If you are unsure where you are in your hormonal journey, start with a free symptom check to understand your symptom pattern. If you have questions and want to think through your options before your next appointment, our AI companion can help you prepare — gathering your symptom history, clarifying what to ask your doctor, and explaining what the evidence actually says.
Frequently Asked Questions
Q: Can I take oestrogen if I am still having periods?
Yes. Perimenopause is characterised by irregular, often still-present periods alongside significant symptoms. HRT can be started during perimenopause while you are still menstruating. In fact, the perimenopausal years — when oestrogen is fluctuating most erratically — are often when symptoms are at their worst, and when treatment provides the greatest relief. Your gynaecologist will prescribe a regimen appropriate to your cycle stage, typically a cyclical or continuous combined regimen depending on your bleeding pattern.
Q: Will oestrogen therapy make me gain weight?
No. Weight gain during perimenopause is driven by hormonal changes, particularly declining oestrogen — not by HRT itself. In fact, some women find that HRT helps with the redistribution of body fat that accompanies perimenopause (specifically the shift toward abdominal fat). Controlled trials do not show that HRT causes weight gain. What it may do is reduce the metabolic disruption and fatigue that makes weight management harder during this transition.
Q: I had a blood clot years ago. Can I still consider oestrogen?
A history of blood clots (DVT or pulmonary embolism) is a reason for careful evaluation, not an automatic disqualification. The key question is whether you use transdermal oestrogen, which bypasses the liver and does not appear to increase clotting risk, even in women with a history of VTE. This is different from oral oestrogen. Women with a prior clot history may still be candidates for transdermal HRT, particularly if the clot had a clear precipitating cause (surgery, long-haul travel, pregnancy). This assessment must be done with a specialist, ideally in conjunction with a haematologist if you have a thrombophilia. In women with certain inherited clotting disorders — particularly antiphospholipid syndrome or severe thrombophilias — even transdermal oestrogen may carry elevated risk. Full haematological assessment is essential before any HRT decision in this group.
Q: My mother had breast cancer. Does that mean I cannot take HRT?
A family history of breast cancer is not a contraindication to HRT. What matters clinically is your own personal history. A family history increases your background breast cancer risk, which is a factor your doctor will discuss with you — but it does not automatically rule out HRT. Many women with a family history of breast cancer use HRT safely under specialist supervision. The decision involves weighing your personal risk level, the severity of your symptoms, the type of HRT under consideration, and your individual values around that risk.
Q: How do I know if my doctor is menopause-aware enough to prescribe HRT?
This is a legitimate concern. Menopause medicine is a subspeciality, and not all gynaecologists are equally current on the evidence. Some indicators that your doctor is menopause-aware: they distinguish between transdermal and oral routes when discussing risk; they mention body-identical or micronised progesterone as an option; they do not cite the 2002 WHI study without contextualising it; they discuss the critical window and do not impose arbitrary time limits on treatment. If your doctor dismisses your symptoms without engaging with treatment options, seeks a second opinion from a gynaecologist affiliated with the Menopause Society of India or a dedicated women’s health clinic.
